Imposed mutational meltdown as an antiviral strategy

Show simplified metadata
dc.contributor.authorJensen, Jeffrey D.
dc.contributor.authorStikeleather, Ryan A.
dc.contributor.authorKowalik, Timothy F.
dc.contributor.authorLynch, Michael
dc.contributor.departmentDepartment of Microbiology and Physiological Systems
dc.date2022-08-11T08:08:09.000
dc.date.accessioned2022-08-23T15:44:35Z
dc.date.available2022-08-23T15:44:35Z
dc.date.issued2020-10-13
dc.date.submitted2020-10-26
dc.description.abstractFollowing widespread infections of the most recent coronavirus known to infect humans, SARS-CoV-2, attention has turned to potential therapeutic options. With no drug or vaccine yet approved, one focal point of research is to evaluate the potential value of repurposing existing antiviral treatments, with the logical strategy being to identify at least a short-term intervention to prevent within-patient progression, whilst long-term vaccine strategies unfold. Here, we offer an evolutionary / population-genetic perspective on one approach that may overwhelm the capacity for pathogen defense (i.e., adaptation) - induced mutational meltdown - providing an overview of key concepts, review of previous theoretical and experimental work of relevance, and guidance for future research. Applied with appropriate care, including target specificity, induced mutational meltdown may provide a general, rapidly implemented approach for the within-patient eradication of a wide range of pathogens or other undesirable microorganisms.
dc.identifier.citation<p>Jensen JD, Stikeleather RA, Kowalik TF, Lynch M. Imposed mutational meltdown as an antiviral strategy. Evolution. 2020 Oct 13. doi: 10.1111/evo.14107. Epub ahead of print. PMID: 33047822. <a href="https://doi.org/10.1111/evo.14107">Link to article on publisher's site</a></p>
dc.identifier.contextkey19982551
dc.identifier.doi10.1111/evo.14107
dc.identifier.issn0014-3820 (Linking)
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/135
dc.identifier.pmid33047822
dc.identifier.submissionpathcovid19/135
dc.identifier.urihttps://hdl.handle.net/20.500.14038/27345
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33047822&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1111/evo.14107
dc.source.journaltitleEvolution; international journal of organic evolution
dc.subjectAntivirals
dc.subjectSARS-CoV-2
dc.subjectlethal mutagenesis
dc.subjectmutational meltdown
dc.subjectpopulation genetics
dc.subjectEvolution
dc.subjectGenetics and Genomics
dc.subjectImmunology and Infectious Disease
dc.subjectInfectious Disease
dc.subjectMicrobiology
dc.subjectPopulation Biology
dc.subjectTherapeutics
dc.subjectVirus Diseases
dc.titleImposed mutational meltdown as an antiviral strategy
dc.typeJournal Article
dspace.entity.typePublication
html.description.abstract<p>Following widespread infections of the most recent coronavirus known to infect humans, SARS-CoV-2, attention has turned to potential therapeutic options. With no drug or vaccine yet approved, one focal point of research is to evaluate the potential value of repurposing existing antiviral treatments, with the logical strategy being to identify at least a short-term intervention to prevent within-patient progression, whilst long-term vaccine strategies unfold. Here, we offer an evolutionary / population-genetic perspective on one approach that may overwhelm the capacity for pathogen defense (i.e., adaptation) - induced mutational meltdown - providing an overview of key concepts, review of previous theoretical and experimental work of relevance, and guidance for future research. Applied with appropriate care, including target specificity, induced mutational meltdown may provide a general, rapidly implemented approach for the within-patient eradication of a wide range of pathogens or other undesirable microorganisms.</p>
Files
Collections
COVID-19 Publications by UMass Chan Authors